The prevalence of PIK3CA mutations has been variously reported in accordance with the different biologic subtypes of BC, which tends to be more common in hormone receptor positive BC (35%) than HER2 positive BC (22–31%) and triple negative BC (8.3%)8,9. This evidence concerns the gene NR4A1 and breast cancer.